Mizuho Securities Keeps Their Buy Rating on Corvus Pharmaceuticals (CRVS)
Mizuho Securities analyst Graig Suvannavejh has maintained a Buy rating on Corvus Pharmaceuticals (CRVS) with a price target of $13.00. The analyst focuses on the Healthcare sector and has an average return of 8.9% with a 50.33% success rate on stock recommendations. Corvus Pharmaceuticals holds a Strong Buy consensus among analysts, with a price target consensus of $13.33.
In a report released today, Graig Suvannavejh from Mizuho Securities reiterated a Buy rating on Corvus Pharmaceuticals, with a price target of $13.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Suvannavejh covers the Healthcare sector, focusing on stocks such as Terns Pharmaceuticals, Immuneering, and Insmed. According to TipRanks, Suvannavejh has an average return of 8.9% and a 50.33% success rate on recommended stocks.
Corvus Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $13.33.
